Unicycive Therapeutics annual current ratio
2020
2021
2022
2023
2024
2025
Unicycive Therapeutics Current Ratio Growth & History (UNCY)
Unicycive Therapeutics's current ratio was 2.59 for fiscal 2025.
View full Unicycive Therapeutics company overviewUnicycive Therapeutics annual current ratio history
| Fiscal year | Period ended | Current ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 2.59 | 1.30 | +101.49% |
| 2024 | 2024-12-31 | 1.28 | 0.52 | +67.91% |
| 2023 | 2023-12-31 | 0.76 | −0.04 | −5.09% |
| 2022 | 2022-12-31 | 0.81 | −7.94 | −90.79% |
| 2021 | 2021-12-31 | 8.75 | 8.68 | +12226.31% |
| 2020 | 2020-12-31 | 0.07 | — | — |
Unicycive Therapeutics quarterly current ratio
Q4.20
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Current ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 3.81 | 1.64 | +75.20% |
| Q1 2026 | 2026-03-31 | 2.40 | 0.76 | +46.31% |
| Q4 2025 | 2025-12-31 | 2.59 | 1.30 | +101.49% |
| Q3 2025 | 2025-09-30 | 3.83 | 0.22 | +6.13% |
| Q2 2025 | 2025-06-30 | 2.18 | −1.19 | −35.35% |
| Q1 2025 | 2025-03-31 | 1.64 | −0.07 | −3.91% |
| Q4 2024 | 2024-12-31 | 1.28 | 0.52 | +67.91% |
| Q3 2024 | 2024-09-30 | 3.61 | 2.41 | +200.35% |
| Q2 2024 | 2024-06-30 | 3.37 | 1.94 | +136.70% |
| Q1 2024 | 2024-03-31 | 1.71 | 0.07 | +4.08% |
| Q4 2023 | 2023-12-31 | 0.76 | −0.04 | −5.09% |
| Q3 2023 | 2023-09-30 | 1.20 | −0.60 | −33.41% |
| Q2 2023 | 2023-06-30 | 1.42 | −3.01 | −67.91% |
| Q1 2023 | 2023-03-31 | 1.64 | −4.80 | −74.53% |
| Q4 2022 | 2022-12-31 | 0.81 | −7.94 | −90.79% |
| Q3 2022 | 2022-09-30 | 1.80 | −23.40 | −92.84% |
| Q2 2022 | 2022-06-30 | 4.43 | 4.25 | +2382.93% |
| Q1 2022 | 2022-03-31 | 6.44 | — | — |
| Q4 2021 | 2021-12-31 | 8.75 | 8.68 | +12226.31% |
| Q3 2021 | 2021-09-30 | 25.20 | — | — |
| Q2 2021 | 2021-06-30 | 0.18 | — | — |
| Q4 2020 | 2020-12-31 | 0.07 | — | — |
Unicycive Therapeutics current ratio trends
Over the last five fiscal years, Unicycive Therapeutics's current ratio increased from 0.07 to 2.59, a change of 2.51. The latest reported quarter, Q2 2026, shows 3.81.
About the metric
What the current ratio means
The current ratio compares short-term assets with obligations due within roughly one year. A higher ratio generally indicates more short-term balance-sheet coverage, but normal levels vary by industry and business model.
Calculation and source
How the current ratio is calculated
TickerStat calculates the current ratio as SEC-reported current assets divided by SEC-reported current liabilities for the same balance-sheet date. Periods without a positive current-liability value are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Unicycive Therapeutics source filings ↗